Chemours Company (The) (NYSE:CC) released its quarterly earnings data on Thursday. The specialty chemicals company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.17, Bloomberg Earnings reports. The business had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.59 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.61 EPS.

In other Chemours Company (The) news, insider E Bryan Snell sold 10,000 shares of Chemours Company (The) stock in a transaction on Friday, August 11th. The shares were sold at an average price of $46.24, for a total value of $462,400.00. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, SVP David C. Shelton sold 5,908 shares of Chemours Company (The) stock in a transaction on Friday, October 13th. The stock was sold at an average price of $56.01, for a total transaction of $330,907.08. Following the completion of the transaction, the senior vice president now directly owns 47,356 shares in the company, valued at $2,652,409.56. The disclosure for this sale can be found here. Insiders sold 77,142 shares of company stock worth $3,953,265 over the last ninety days. Corporate insiders own 1.14% of the company’s stock.

Several equities analysts recently issued reports on CC shares. BidaskClub cut Chemours Company (The) from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Zacks Investment Research cut Chemours Company (The) from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 18th. Citigroup Inc. raised Chemours Company (The) from a “neutral” rating to a “buy” rating and upped their price objective for the company from $43.00 to $45.00 in a research report on Wednesday, July 5th. Jefferies Group LLC upped their price objective on Chemours Company (The) to $60.00 and gave the company a “buy” rating in a research report on Thursday, August 3rd. Finally, Argus reaffirmed a “buy” rating and issued a $55.00 price objective (up from $50.00) on shares of Chemours Company (The) in a research report on Thursday, August 10th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $52.75.

TRADEMARK VIOLATION NOTICE: “Chemours Company (The) (CC) Issues Quarterly Earnings Results, Beats Estimates By $0.17 EPS” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/11/02/chemours-company-the-cc-issues-quarterly-earnings-results-beats-estimates-by-0-17-eps.html.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Earnings History for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.